Celcuity Expenses Jump 81 Percent

Celcuity (NASDAQ:CELC), a clinical-stage biotechnology company developing targeted therapies for cancer, released its second quarter 2025 earnings on August 14, 2025. The highlight was topline Phase 3 data for lead drug gedatolisib, which showed unprecedented results in advanced breast cancer patients. The company posted a non-GAAP EPS loss of ($0.93), wider than the analyst consensus estimate of ($0.88) non-GAAP. Total operating expenses climbed to $44.0 million as development efforts expanded, contributing to a net loss (non-GAAP) that missed expectations. Despite the higher loss, Celcuity showcased strong clinical momentum and increased its cash position with a major capital raise, supporting operations through 2027. The quarter positioned Celcuity at a turning point as it transitions from research to pursuing commercial drug approval. Source: Analyst estimates for the quarter provided by FactSet. Celcuity is a clinical-stage biotechnology company focused on discovering and developing targeted therapies for cancer. Its core strategy centers around gedatolisib, an investigational small molecule designed to inhibit multiple cancer-driving enzymes in cell signaling pathways. Gedatolisib targets two major molecular pathways, PI3K and mTOR, which are often implicated in resistance to existing cancer treatments.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool